EP1012333A1 - ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23 - Google Patents

ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23

Info

Publication number
EP1012333A1
EP1012333A1 EP98938406A EP98938406A EP1012333A1 EP 1012333 A1 EP1012333 A1 EP 1012333A1 EP 98938406 A EP98938406 A EP 98938406A EP 98938406 A EP98938406 A EP 98938406A EP 1012333 A1 EP1012333 A1 EP 1012333A1
Authority
EP
European Patent Office
Prior art keywords
cells
cell
seq
senescent
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938406A
Other languages
English (en)
French (fr)
Other versions
EP1012333A4 (de
Inventor
Karen Swisshelm
Suzanne Hosier
Manfred Kubbies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP1012333A1 publication Critical patent/EP1012333A1/de
Publication of EP1012333A4 publication Critical patent/EP1012333A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This enzyme's presence can be detected easily by providing cells with a substrate that yields a blue-colored product upon enzymatic cleavage.
  • these investigators observed an age-dependent rise in this senescence-associated ⁇ -galactosidase in human skin, suggesting that the accumulation of the enzyme provides a marker for senescence in fibroblasts and keratinocytes in the skin and perhaps other epithelial tissues.
  • senescence may have evolved as a mechanism for tumor suppression, and that aging is an indirect effect of this circumstance. Because constraints on growth control are absent from tumor cells, such cells most likely have switched off the expression of genes whose products promote or maintain the senescent state. For example, in vitro studies have indicated that senescence can be partially circumvented by the inactivation of tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
  • tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
  • a novel gene has been identified that is expressed at high levels in senescent cells.
  • a cDNA corresponding to the novel gene has been isolated and sequenced and found to contain an open reading frame encoding a protein having a deduced molecular weight of 23 kilodaltons (kDa) (SEQ ID NO: l).
  • kDa kilodaltons
  • this gene has been named "p23.”
  • Messenger RNA transcribed from p23 is reproducibly detectable at higher levels in senescent than in proliferating cultured normal human mammary epithelial cells.
  • p23 The function of p23 is not known, but analysis of its deduced amino acid sequence (SEQ ID NO:2) suggests that it belongs to a family of transmembrane proteins known as the "PMP 22" family or "epithelial membrane protein” (EMP) family (e.g., see Taylor et al., J. Biol. Chem. 270:28824-28833, 1995; Lobsiger et al., Genomics 36:379-387, 1996; Taylor and Suter, Gene 175:115-120. 1996).
  • PMP 22 family
  • EMP epidermal membrane protein
  • Immunospecific reagents capable of specifically binding p23 may be produced by hybridoma or by repeated injection of the purified protein or selected peptides derived from p23 in combination with an appropriate adjuvant (e.g., Freund's, ISCOMs, or the like) into a suitable animal such as a rabbit, sheep, or goat.
  • an appropriate adjuvant e.g., Freund's, ISCOMs, or the like
  • Therapeutic applications include binding partners that inhibit the binding of p23 to ligands that normally bind to it. thus promoting cell proliferation in the treated cell.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP98938406A 1997-08-08 1998-08-05 ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23 Withdrawn EP1012333A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90887397A 1997-08-08 1997-08-08
US908873 1997-08-08
PCT/US1998/016343 WO1999007893A1 (en) 1997-08-08 1998-08-05 ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23

Publications (2)

Publication Number Publication Date
EP1012333A1 true EP1012333A1 (de) 2000-06-28
EP1012333A4 EP1012333A4 (de) 2003-01-02

Family

ID=25426353

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938406A Withdrawn EP1012333A4 (de) 1997-08-08 1998-08-05 ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23

Country Status (9)

Country Link
EP (1) EP1012333A4 (de)
JP (1) JP2001512698A (de)
KR (1) KR20010022741A (de)
CN (1) CN1270637A (de)
AU (1) AU8693598A (de)
BR (1) BR9811865A (de)
CA (1) CA2296598A1 (de)
TR (1) TR200000331T2 (de)
WO (1) WO1999007893A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024721A1 (en) * 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
EP1248839B1 (de) * 2000-01-21 2010-04-07 Polymun Scientific Immunbiologische Forschung GmbH Tumor- und seneszenzsmarker
AU750296B2 (en) 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
WO2002101075A2 (en) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2009248945B2 (en) 2008-05-23 2014-02-13 Siwa Corporation Methods, compositions and apparatuses for facilitating regeneration
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2017143073A1 (en) 2016-02-19 2017-08-24 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013610A2 (en) * 1994-10-31 1996-05-09 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580726A (en) * 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
WO1999007850A1 (en) * 1997-08-06 1999-02-18 Millennium Biotherapeutics, Inc. Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
CA2332379A1 (en) * 1998-06-29 2000-01-06 Incyte Pharmaceuticals, Inc. Molecules associated with apoptosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013610A2 (en) * 1994-10-31 1996-05-09 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] 211 aa, 15 June 1999 (1999-06-15) "Human Tango-73 protein" retrieved from EBI Database accession no. AAY04143 XP002217495 -& WO 99 07850 A 18 February 1999 (1999-02-18) *
DATABASE EMBL [Online] 211 aa, 7 December 1999 (1999-12-07) "Human PRO944 protein sequence" retrieved from EBI Database accession no. AAY41726 XP002217497 -& WO 99 46281 A 16 September 1999 (1999-09-16) *
DATABASE EMBL [Online] 2747 bp, 7 December 1999 (1999-12-07) "Human PRO944 nucleotide sequence" retrieved from EBI Database accession no. AAZ34118 XP002217498 -& WO 99 46281 A 16 September 1999 (1999-09-16) *
DATABASE EMBL [Online] 3400 pb, 5 May 2000 (2000-05-05) "cDNA encoding a human molecule associated with apoptosis 2 (MAPOP-2)" retrieved from EBI Database accession no. AAZ60459 XP002217494 & WO 00 00609 A 6 January 2000 (2000-01-06) *
DATABASE EMBL [Online] 3483 pb, 15 June 1999 (1999-06-15) "Human Tango-73 encoding cDNA" retrieved from EBI Database accession no. AAX19956 XP002217496 -& WO 99 07850 A 18 February 1999 (1999-02-18) *
DATABASE EMBLLEVANT [Online] 211 aa, 5 May 2000 (2000-05-05) "A human molecule associated with apoptosis 2 (MAPOP-2)" retrieved from EBI Database accession no. AAY68679 XP002217493 -& WO 00 00609 A 6 January 2000 (2000-01-06) *
FURUSE M ET AL: "CLAUDIN-1 AND -2: NOVEL INTEGRAL MEMBRANE PROTEINS LOCALIZING AT TIGHT JUNCTIONS WITH NO SEQUENCE SIMILARITY TO OCCLUDIN" JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 141, no. 7, 29 June 1998 (1998-06-29), pages 1539-1550, XP001008152 ISSN: 0021-9525 *
JONASDOTTIR A. ET AL.: "Refinement of the dominant optic atrophy locus (OPA1) to a 1.4-cM interval on chromosome 3q28-3q29 within a 3-Mb YAC contig" ORIGINAL INVESTIGATION, vol. 99, 1997, pages 115-120, XP002217491 *
LINSKENS M H K ET AL: "CATALOGING ALTERED GENE EXPRESSION IN YOUNG AND SENESCENT CELLS USING ENHANCED DIFFERENTIAL DISPLAY" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 16, 1995, pages 3244-3251, XP002047039 ISSN: 0305-1048 *
See also references of WO9907893A1 *
SMITH D. ET AL.: "Localization of 616 human chromosome 3-specific cosmids using a somatic cell hybrid deletion mapping panel" GENOMICS, vol. 11, September 1991 (1991-09), pages 179-187, XP001107125 *
SWISSHELM K ET AL: "SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 226, no. 2, 21 January 1999 (1999-01-21), pages 285-295, XP004155143 ISSN: 0378-1119 *

Also Published As

Publication number Publication date
EP1012333A4 (de) 2003-01-02
WO1999007893A1 (en) 1999-02-18
JP2001512698A (ja) 2001-08-28
AU8693598A (en) 1999-03-01
KR20010022741A (ko) 2001-03-26
BR9811865A (pt) 2000-08-15
TR200000331T2 (tr) 2000-05-22
CN1270637A (zh) 2000-10-18
CA2296598A1 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
EP1012333A1 (de) ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23
WO1996002552A1 (en) Lung cancer marker
WO2003101388A2 (en) Human solute carrier family 7 member 11 (hslc7a11)
Fernandez-Pol et al. A growth factor-inducible gene encodes a novel nuclear protein with zinc finger structure.
JP2002525067A (ja) レプチン誘導遺伝子
JP2003508030A (ja) 新規ポリペプチドおよびそれをコードする核酸
EP1048727B1 (de) Gen, welches für neues transmembranprotein kodiert
US6987004B1 (en) Genes integrating signal transduction pathways
KR100869190B1 (ko) 암세포 증식 조절에 유용한 폴리뉴클레오티드
US6586581B1 (en) Prolactin regulatory element binding protein and uses thereof
US20050196753A1 (en) Human coactivator-associated arginine methyltransferase 1 (hCARM1)
AU776341B2 (en) Meg-1 protein
AU762987B2 (en) Chondrosarcoma associated genes
EP1146053A1 (de) Protein meg-4
JP2006525031A (ja) Ａｃｈｅｒｏｎ発現の制御方法
US6342594B1 (en) Nucleic acid which is upregulated in metastatic human tumor cells
US7309783B2 (en) Mammalian early developmental regulator gene
WO2002026809A1 (fr) Nouveau polypeptide, proteine transmembranaire 35.31 possedant un domaine permettant la duplication de facteurs de croissance epidermique, et polynucleotide codant ce polypeptide
US20030109016A1 (en) TSLL1 gene
US20020123092A1 (en) Regulatory elements from RP1 gene and uses thereof
Mattei et al. Human CREM Gene: Evolutionary Conservation, Chromosomal Localization, and Inducibility of the Transcript’
WO2001021649A2 (en) Nucleic acids encoding vitamin d response element binding proteins, products related thereto, and methods of using same
WO2001049734A1 (fr) Nouveau polypeptide, proteine plp 10, et polynucleotide codant pour ce polypeptide
WO2001079467A2 (en) Identification of a renal nadph oxidase
JP2002325580A (ja) ヒト腫瘍細胞において増加調節される核酸、それによりコードされるタンパク質、及び腫瘍の診断方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030116